MAPT and Alzheimer disease: Moreover, very recently presented clinical trial data regarding the approved anti-Aβ immunotherapies [75], suggests that gantenerumab can efficiently reduce amyloid plaques down to a level indistinguishable from a healthy person and slow, but not stop, AD progression if administered early, potentially because accumulation of tau tangles is not reversed and further buildup is only slowed down but not prevented [76,77].